查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1544544

抗肥胖药物市场、机会、成长动力、产业趋势分析与预测，2024-2032

Anti-Obesity Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 200 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在药物开发的不断推出和创新的带动下，抗肥胖药物市场规模预计从 2024 年到 2032 年将以 27% 的复合年增长率扩大。

新的抗肥胖药物正在推出，以提高控制体重的功效和安全性。对肥胖生物学机制的持续研究和进展正在推动更具针对性和更有效的抗肥胖药物的开发。此外，基因组学和生物技术的创新正在促进针对肥胖患者的不同需求开发精准疗法。例如，2024 年 1 月，抗肥胖药物 Zepbound 的製造商礼来公司 (Eli Lilly) 推出了直接面向患者的入口网站 LillyDirect。此措施旨在提高抗肥胖药物的可近性，同时简化治疗过程并提高患者的参与度。

整个市场分为产品、行动途径、配销通路和区域。

从产品来看，由于体重管理解决方案的需求不断增长，预计 2024 年至 2032 年，非处方药领域的抗肥胖药物市场价值将以显着的复合年增长率增长。 OTC（非处方药）选项使个人无需处方即可更轻鬆地对抗肥胖。这些非处方抗肥胖药物还具有有效的成分和更安全的特性，支持减肥努力。

到 2032 年，抗肥胖药物市场的电子商务配销通路领域将经历大幅增长。由于便利性和更广泛的选择，消费者开始转向电子商务平台购买抗肥胖药物。线上零售商也在使其产品多样化，推出各种配方和品牌，以满足追求体重管理解决方案的人们的需求。

亚太地区抗肥胖药物市场预计到 2032 年将显着成长，这主要是由于医疗保健支出不断增加。医疗保健投资的增加正在将更多资源投入到抗肥胖治疗的开发和销售中。因此，随着医疗保健支出持续增加，将促进抗肥胖药物的扩展和可近性。这确保了更广泛的人群能够获得有效的肥胖管理解决方案，最终提高该地区的整体健康水平。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 肥胖相关疾病的盛行率不断增加
      • 政府法规和指南
      • 技术进步的增加
    • 产业陷阱与挑战
      • 副作用和不良反应
      • 抗肥胖药物成本高
  • 成长潜力分析
  • 监管环境
  • 技术景观
    • 核心技术
    • 邻近技术
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 处方药
  • 非处方药

第 6 章：市场估计与预测：按行动路径，2021 - 2032

  • 主要趋势
  • 週边作用药物
  • 中枢作用药物

第 7 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 药妆店
  • 电子商务

第 8 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 9 章：公司简介

  • Arena Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Currax Pharmaceuticals LLC
  • Eli Lily and Co
  • F. Hoffmann-La Roche Ltd.
  • Gelesis
  • GlaxoSmithKline plc
  • Merck and Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics, Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Vivus, Inc.
简介目录
Product Code: 10074

Anti-Obesity Drugs Market size is projected to expand at a 27% CAGR from 2024 to 2032, led by increasing launches and innovations in drug development.

New anti-obesity medications are being introduced to offer improved efficacy and safety profiles for managing weight. Ongoing research and advancements in understanding the biological mechanisms of obesity are driving the development of more targeted and effective anti-obesity drugs. Furthermore, innovations in genomics and biotechnology are facilitating the creation of precise therapies tailored to the diverse needs of individuals grappling with obesity. For instance, in January 2024, Eli Lilly, the maker of the anti-obesity drug Zepbound, launched LillyDirect, a direct-to-patient portal. This initiative aimed to enhance access to anti-obesity medications while simplifying the treatment process and boosting patient engagement.

The overall market is segregated into product, action pathway, distribution channel, and region.

Based on product, the anti-obesity drugs market value from the OTC drugs segment is estimated to rise at a significant CAGR from 2024 to 2032, attributed to the growing demand for weight management solutions. OTC (over-the-counter) options are granting individuals easier access to combat obesity without needing a prescription. These OTC anti-obesity drugs also boast effective ingredients and safer profiles, bolstering weight loss endeavors.

The e-commerce distribution channel segment in the anti-obesity drugs market is set to experience substantial growth until 2032. This is driven by the increasing demand for accessible treatments. Consumers are turning to e-commerce platforms for their anti-obesity medications, drawn by convenience and wider selection. Online retailers are also diversifying their offerings, presenting various formulations and brands to cater to those pursuing weight management solutions.

Asia Pacific anti-obesity drugs market is poised for notable growth by 2032, largely due to escalating healthcare expenditures. Heightened investments in healthcare are channeling more resources into the development and distribution of anti-obesity treatments. Consequently, as healthcare expenditures continue to rise, they will bolster the expansion and accessibility of anti-obesity drugs. This that ensures a broader segment of the population can access effective solutions for obesity management, ultimately enhancing overall health in the region.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of obesity-related conditions
      • 3.2.1.2 Government regulations and guidelines
      • 3.2.1.3 Increase in technological advancements
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Side effects and adverse reactions
      • 3.2.2.2 High cost of anti-obesity drugs
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
    • 3.5.1 Core technologies
    • 3.5.2 Adjacent technologies
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Prescription drugs
  • 5.3 OTC drugs

Chapter 6 Market Estimates and Forecast, By Action Pathway, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Peripherally acting drugs
  • 6.3 Centrally acting drugs

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Drug stores
  • 7.5 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Arena Pharmaceuticals, Inc.
  • 9.2 AstraZeneca PLC
  • 9.3 Boehringer Ingelheim International GmbH
  • 9.4 Currax Pharmaceuticals LLC
  • 9.5 Eli Lily and Co
  • 9.6 F. Hoffmann-La Roche Ltd.
  • 9.7 Gelesis
  • 9.8 GlaxoSmithKline plc
  • 9.9 Merck and Co., Inc.
  • 9.10 Novartis AG
  • 9.11 Novo Nordisk A/S
  • 9.12 Orexigen Therapeutics, Inc.
  • 9.13 Pfizer Inc.
  • 9.14 Rhythm Pharmaceuticals, Inc.
  • 9.15 Vivus, Inc.